RxDoctor Payments Data

Rose Graham, NP

Nurse Practitioner · Fayetteville, NCNPI 1609302868

Payments from drug & device makers

$1,207in general payments, 2019–2025

Across 92 payments — averaging $13.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$707
  • Actelion Pharmaceuticals US, Inc.$165
  • Boehringer Ingelheim$62
  • AstraZeneca$58
  • United Therapeutics Corporation$44
  • Regeneron Healthcare Solutions, Inc.$44
  • plus $126 from 5 others

What the payments were for

  • Food & beverage$1,18598%
  • Education$222%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,207 in reported general payments places this provider in the 80th percentile of 4,393 nurse practitioner providers in North Carolina.

See all nurse practitioner providers in North Carolina

Medicare billing

Part B allowed, 2024
$74,068
Medicare patients
385
Services billed
710

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter270$332,102
Breztri AerosphereBudesonide/Glycopyr/Formoterol62$43,670
Breo ElliptaFluticasone/Vilanterol41$42,427
SymbicortBudesonide/Formoterol Fumarate103$39,316
Spiriva HandihalerTiotropium Bromide46$31,642
Advair HfaFluticasone Propion/Salmeterol64$25,021
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr19$20,604
Albuterol Sulfate HfaAlbuterol Sulfate574$17,152
Spiriva RespimatTiotropium Bromide23$14,840
Ventolin HfaAlbuterol Sulfate190$13,109
Atrovent HfaIpratropium Bromide15$11,590
Stiolto RespimatTiotropium Br/Olodaterol Hcl14$11,241
Combivent RespimatIpratropium/Albuterol Sulfate11$10,413
Advair DiskusFluticasone Propion/Salmeterol27$7,646
Fluticasone-Salmeterol HfaFluticasone Propion/Salmeterol11$3,980

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$707$395,134330 claims
AstraZenecaBreztri Aerosphere, Symbicort$58$82,986165 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat, Combivent Respimat$62$36,49448 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,393 nurse practitioner providers in North Carolina.

Other nurse practitioner in Fayetteville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →